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A 57 year old G4P3013 woman presented with post-menopausal
bleeding, and an endometrial biopsy showed FIGO Grade I endometrioid
adenocarcinoma. Although offered surgical treatment, the patient initial-
ly opted for megestrol acetate at 40 mg once a day. Repeat biopsy after
4 months of therapy showed persistent endometrioid carcinoma with
features suspicious for papillary serous carcinoma. The patient then
underwent a robotic-assisted hysterectomy and bilateral salpingo-
oophorectomy with staging. Grossly the 129 g uterus contained a
3.5 cm polypoid tumor within the endometrial cavity. Microscopic ex-
amination showed a mixed epithelial carcinoma with 50% FIGO Grade I
endometrioid and 50% serous histologies (Figs. 1A & B). The tumor
showed stromal invasion of the cervix without lymph node, ovarian, or
omental involvement, corresponding to FIGO Stage II disease. Post-
operatively she received whole pelvis radiation with brachytherapy
followed by six cycles of carboplatin and paclitaxel. Currently she is dis-
ease free ﬁve months after completing treatment.
Materials and methods
Immunohistochemical and molecular analyses were performed on
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Open access under CC BY-NC-ND license.containing both morphologies, endometrioid and serous, of the mixed
epithelial tumor. Immunohistochemical analysis for p53 protein
(DAKO, California)was performed at a 1:200 dilution using the Ventana
© UltraView DAB kit, Cat#760-500.
Three distinct areas (high-grade serous, p53 IHC positive;
low-grade endometrioid, p53 IHC positive; low-grade endometrioid,
p53 IHC negative) were separately evaluated for TP53 mutation sta-
tus. Brieﬂy, 10 μm sections were stained with hematoxylin and each
area was separately microdissected. DNA from each area was sepa-
rately extracted using QiaAMP FFPE extraction kit (Qiagen, Inc.)
according to manufacturer's instructions. Following DNA extraction,
the samples were evaluated for mutation in exons 5, 6, 7 and 8 of
the TP53 gene. PCR ampliﬁcation was performed using primers as
previously described using the KAPA2G™ Robust HotStart Enzyme
and PCR master mix with KAPA™ dNTP mix (KAPA Biosystems cat#
KK5525 and KK1017) in a 25 μl reaction (Franklin et al., 1997). PCR
was performed on an ABI 9700 thermocycler with an initial denatur-
ing step at 95 °C followed by 20 cycles of touchdown PCR (starting
annealing temperature of 65 °C, decremented 0.5 °C per cycle) and
25 cycles at 94 °C denaturation, 55 °C annealing and 72 °C extension
ﬁnished by a 10 min 72 °C ﬁnal extension. The resultant PCR products
were puriﬁed with the QIAquick 96 well PCR cleanup kit (Qiagen cat#
28106). The puriﬁed PCR products were sequenced in forward and
reverse directions using an ABI 3730 automated sequencer and also
using BigDye Terminator Version 1.1 (Applied Biosystems). Each
chromatogram was visually inspected for any abnormalities using
the human TP53 GenBank ID NM_000546.5 as the reference sequence.
Sequences were also evaluated using Mutation Surveyor software
(Soft Genetics, State College, PA) using the same GenBank ID refer-
ence sequence for comparison. Mutations were determined to be
present when peaks reached a threshold value above baseline calcu-
lated from background level, combined with visual inspection of the
chromatogram.Results
Immunohistochemistry for p53 protein showed strong diffuse posi-
tivity in the serous component, andwas negative in the vast majority of
the endometrioid component. There was, however, patchy strong posi-
tivity in areas of endometrioid adenocarcinoma (Figs. 1C & D). In these
three discrete areas, two distinct TP53 gene mutations were identiﬁed.
The p53 protein negative and positive endometrioid components
Fig. 1. A: H&E stained section demonstrating serous and low-grade endometrioid histologies (40×). B: H&E stained section of alternate area of low-grade endometrioid carcinoma
(40×). C: p53 immunohistochemical preparation (DAKO, California) of serous and low-grade histologies (40×). D: p53 immunohistochemical preparation (DAKO, California) of
alternate area of low-grade endometrioid carcinoma (40×).
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protein positive serous component showed two mutations in exon 8,
the ﬁrst being R273H (c.818 G>A) and the second a previously
unreported R306* (c.916C>T) (Fig. 2). The ﬁndings are summarized
in Table 1.
Discussion
Endometrial endometrioid and serous carcinomas are thought to
be driven by two distinct molecular mechanisms, the former by estro-
gen stimulation and the latter by early TP53 gene mutation (Bansal et
al., 2009; Tashiro et al., 1997). These discrete molecular mechanisms
account for the differences in clinicopathologic behavior and progno-
sis, however difﬁculties arise when both histologic subtypes are present.
Although there are theories explaining the presence of mixed endo-
metrial carcinomas, the underlying molecular differences have not
been fully explored (Matias-Guiu et al., 2001). By independently
evaluating the TP53 gene in areas of differing histology and p53Fig. 2. Chromatogram of TP53 gene exon 8, demonstrating R273H (c.818 Gprotein immunoreactivity, we attempted to gain insight into the mo-
lecular relationship of histologically distinct lesions occurring con-
currently. The TP53 gene located on chromosome 17p13.1 acts as a
tumor suppressor gene via multiple well-described mechanisms. Its
wild-type protein product inhibits cell proliferation via G1/S arrest,
activates apoptotic pathways, and initiates DNA mismatch repair.
The normal coding region contains 11 exons, and single base substi-
tutions in highly conserved regions are common, which can lead to
missense mutations. Non-functional, mutant p53 protein product is
more stable in vivo, leading to intracytosolic accumulation, which
aids in detection of p53 protein by immunohistochemistry. It has
been shown that, although not 100% sensitive, p53 protein immuno-
reactivity is strongly correlated to underlying mutation status
(Kohler et al., 1992).
Serous carcinoma commonly shows an early mutation in the TP53
gene, as evidenced by its precursor lesion, endometrial intraepithelial
carcinoma (EIC) demonstrating TP53 gene mutations in a majority of
cases (Tashiro et al., 1997). Endometrioid carcinoma, however, has>A) substitution (top) and R306* (c.916C>T) substitution (bottom).
Table 1
Immunohistochemistry and gene mutation status in histologically distinct areas of
tumor
Histology FIGO grade I
endometrioid
FIGO grade I
endometrioid
Serous
p53
immunohistochemistry
Negative Positive Positive
TP53 gene mutation Positive
(R273H)
Positive
(R273H)
Positive (R273H, and
R306*)
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later stages and in higher grade tumors (Mhawech-Fauceglia et al.,
2010). Many studies have investigated either TP53 gene mutation or
p53 protein expression in mixed tumors, but correlation of the two
has not been well described (Koul et al., 2002). It has also been
shown that despite the underlying data regarding the correlation of
mutation and overexpression in serous tumors, the presence of p53
immunohistochemical positivity in mixed tumors may not correlate
well with underlying TP53 gene mutation status (Sherman et al.,
1995; Lee et al., 2010).
This case showed different patterns of staining with p53 antibody
between areas with endometrioid and serous histologies; the serous
component was strongly and diffusely positive while the endometrioid
component was largely negative. There were, however, focal areas of
histologically low-grade endometrioid carcinomawith strong immuno-
reactivity for p53 protein. The differing expression patterns raise the
question of how well p53 protein immunoreactivity and TP53 gene
mutation correlate, and what positive p53 protein immunostaining
indicates on a molecular level. Via TP53 mutational analysis, we found
an R273H (c.818 G>A) mutation in exon 8 in both endometrioid and
serous areas, irrespective of p53 protein immunoreactivity. The serous
component showed an additional, novel R306* (c.916C>T) mutation
in exon 8. Finding a TP53mutation in p53 negative endometrioid carci-
noma does not alignwith conventional thinking regarding the develop-
ment of mixed tumors and suggests that in this case, the R273H
(c.818 G>A) mutation was likely an early event. This further suggests
that with a “second hit” in the form of an additional exon 8 R306*
(c.916C>T) mutation, the tumor acquired a higher grade (serous) his-
tology and presumptively a more aggressive biologic potential. We
hypothesize that the second mutation, R306* (c.916C>T), further
altered the p53 protein product, leading to increased intracytosolic pro-
tein accumulation, and therefore stronger reactivity by immunohisto-
chemistry. Although there is a single reported case of pure serous
carcinoma of the endometrium with the R273H (c.818 G>A) mutation
in exon 8 of the TP53 gene (Sakuragi et al., 2001), this is the ﬁrst caseto describe the R306* (c.916C>T) mutation in this setting, and the
only case thus far documenting two concomitant TP53 gene mutations
in a single endometrial tumor. Our ﬁndings raise the possibility that
type I and type II tumors may be more closely related than previously
thought, as evidenced by a common TP53 genemutation arising in histo-
logically distinct areas of the same tumor. Itmay be that a unique process
of carcinogenesis accounts for the mixed epithelial subtypes in endome-
trial carcinoma via thewell-established “two-hit” hypothesis. Further re-
search into mixed epithelial tumors, with particular attention to their
genetic proﬁles may further elucidate mechanisms of carcinogenesis.
Additional characterization of TP53 gene mutation status in FIGO Grade
I endometrioid carcinoma may reveal mutations unsuspected based on
histology, and may better classify these lesions as to their potential clin-
ical behavior, guiding clinical follow-up and treatment strategies.
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